2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1737

Adherence to Subcutaneous Biological Therapies Among Inflammatory Arthropaty Patients from a University Hospital
Abstract Number: 1738

Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Adalimumab Using a Matching-Adjusted Indirect Comparison
Abstract Number: 1739

Comparative Effectiveness of Secukinumab and Adalimumab in Ankylosing Spondylitis As Assessed By Matching-Adjusted Indirect Comparison: An Analysis Based on All Pivotal Phase 3 Clinical Trial Data
Abstract Number: 1740

Long-Term Improvements in Physical Function of DMARD-Naive and DMARD/Biologic-Experienced Psoriatic Arthritis Patients Treated with Apremilast: Data from a Large Database of 4 Phase III Clinical Trials
Abstract Number: 1741

Patients with Active Psoriatic Arthritis Achieving Minimal Disease Activity with Secukinumab Treatment Demonstrate Sustained Improvement of Function and Quality of Life
Abstract Number: 1742

Effect of DMARD Therapies on NSAID Intake, Quality of Life, and Physical Functioning in Patients with Ankylosing Spondylitis
Abstract Number: 1743

Prevalence of Inflammatory Neck Pain in a Cohort of Patients with Psoriatic Arthritis and Its Association with Clinical and Radiographic Features
Abstract Number: 1744

Expression of C1q By Podocytes at Late Stages of Proliferative Lupus Glomerulonephritis
Abstract Number: 1745

Disturbance of Renal Circadian Rhythm in Lupus Nephritis
Abstract Number: 1746

Immune Complex-Induced IL-6 Production By Lupus Prone Mesangial Cells Is Mediated By Neuraminidase Activity
Abstract Number: 1747

Dissecting the Role of Single Complement Deficiencies in a Novel Model for Apoptotic Cell-Induced Lupus
Abstract Number: 1748

Effects of Anti-High Mobility Group Box 1 Antibody for MRL/Lpr lupus-Prone Mice
Abstract Number: 1749

The Role of Mucosal-Associated Invariant T (MAIT) Cells in Lupus Dermatitis
Abstract Number: 1750

Down-Regulation of microRNA-200a-3p, Targeting C-Terminal Binding Protein-2 (CtBP2), Is Involved in Hypoproduction of IL-2 in SLE-Derived T Cells
Abstract Number: 1751

Coagulation Pathway Function in Ischemia/Reperfusion Tissue Injury in Autoimmune Prone Mice

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].